Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults



Status:Archived
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years


The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1
Vaccine in healthy adults.



We found this trial at
2
sites
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
1010 Carondelet Drive
Kaw, Missouri 64114
816-943-0770
?
mi
from
Kaw, MO
Click here to add this to my saved trials